- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05796648
Preparing a Food is Medicine Intervention to Promote Healthy Eating and Blood Pressure Control
January 6, 2025 updated by: Saria Lofton, University of Illinois at Chicago
Preparing a Food is Medicine Intervention to Promote Healthy Eating and Blood Pressure Control in Black Women with Hypertension and Obesity
Hypertension and obesity are both major risk factors for cardiovascular disease (CVD), a leading cause of death for Black women in the United States.
The investigators propose examining the feasibility and acceptability of the 12-week RN-CHeFRx (Real Nourishment and Cooking Healthy Food is Rx) intervention - grocery delivery, cooking classes, and nutrition education - for Black women with hypertension and obesity to improve nutritious eating habits and blood pressure control.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The objective of this study is to conduct the RN-CHeFRx (Real Nourishment and Cooking Healthy Food is Rx) for 12 weeks among Black women who are obese and hypertensive living Chicago.
We propose to 1) Pilot the RN-CHEFRx intervention and measures that will be used to assess blood pressure, BMI status, and sodium intake with 20 Black women diagnosed with hypertension and BMI ≥ 30.
We will assess the efficacy of the evaluation tools to be used in a future clinical trial at three-time points (baseline, 12 weeks, and 6 months); and 2) Assess the feasibility and acceptability of the RN-CHeFRx intervention using interviews, surveys, and documentary analysis.
Findings from this study will inform a larger efficacy trial of RN-CHeFRx to improve dietary behaviors and blood pressure control among Black women with hypertension and obesity.
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- University of Illinois Chicago
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 99 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- self-identified as Black or of African descent
- female
- ≥ 18 years old
- baseline blood pressure ≥130/85 or diagnosed with hypertension and BMI ≥ 30
Exclusion Criteria:
- inability to cook in their homes
- cognitive deficits impeding the ability to participate or provide informed consent
- current treatment for cancer
- liver or renal disease
- pregnancy
- lack of English language proficiency
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Food is Medicine approach
Groups of 10 will attend a 12 week intervention that includes cooking classes, grocery delivery and nutrition education.
|
The RN-CHeFRx trial to enhance dietary intake and blood pressure control in Black women with hypertension and obesity compared to usual care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants who complete the 12 week intervention
Time Frame: Up to 12 weeks
|
Completion will be measured by class attendance
|
Up to 12 weeks
|
|
Number of participants recruited
Time Frame: Up to 12 weeks
|
Patients recruited, screened, eligible and consented to participate in the study
|
Up to 12 weeks
|
|
Number of participants who complete data collection visits
Time Frame: Baseline to 4 months
|
Completion measured by participants completing surveys, blood pressure measurements, and those who provide blood biospecimens
|
Baseline to 4 months
|
|
Acceptability of the intervention
Time Frame: Up to 12 weeks
|
Assessed via participant feedback
|
Up to 12 weeks
|
|
Change in mean blood pressures (mmHg) during intervention
Time Frame: Baseline to 12 weeks
|
Change will be measured by comparing blood pressures from baseline to 12 weeks
|
Baseline to 12 weeks
|
|
dietary intake during intervention
Time Frame: Baseline to 12 weeks
|
Dietary intake at baseline and 12 weeks
|
Baseline to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in body weight during intervention
Time Frame: Up to 12 weeks
|
Change will be measured by comparing body weight obtained at baseline and 12 weeks
|
Up to 12 weeks
|
|
Change in body weight at 6 months
Time Frame: 12 weeks to 24 weeks
|
Change will be measured by comparing body weight (kg) obtained at 12 weeks and at 24 weeks.
|
12 weeks to 24 weeks
|
|
Change in blood pressure at 6 months
Time Frame: 12 weeks to 24 weeks
|
Change will be measured by comparing systolic and diastolic blood pressure at 12 weeks to 24 weeks
|
12 weeks to 24 weeks
|
|
Dietary intake during post-intervention
Time Frame: 12 weeks to 24 weeks
|
Dietary intake from 12 weeks to 24 weeks
|
12 weeks to 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2023
Primary Completion (Actual)
February 15, 2024
Study Completion (Actual)
February 15, 2024
Study Registration Dates
First Submitted
December 13, 2022
First Submitted That Met QC Criteria
April 1, 2023
First Posted (Actual)
April 3, 2023
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
January 6, 2025
Last Verified
November 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-0947
- P50MD017349 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
Abant Izzet Baysal UniversityNot yet recruitingPRIMARY HYPERTENSIONTurkey (Türkiye)
-
SingHealth PolyclinicsNanyang PolytechnicEnrolling by invitationHypertension,EssentialSingapore
-
Hacettepe UniversityBozok UniversityCompletedHypertension | Arterial Hypertension | Systemic HypertensionTurkey (Türkiye)
-
BackBeat Medical IncNot yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEFGeorgia
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension (HTN) | Hypertension ArterialBrazil
Clinical Trials on RN-CHeFRx
-
Marquette UniversityCompletedDischarge Transition of Patients Discharged to HomeUnited States
-
VA Office of Research and DevelopmentCompleted
-
University of CincinnatiWashington State UniversityEnrolling by invitationFatigue | Sleep | Occupational Health | NurseUnited States
-
Rob Surgical Systems S.L.Completed
-
UnitedHealthcareUniversity of California, Los AngelesTerminated
-
University of NebraskaNational Heart, Lung, and Blood Institute (NHLBI); University of Iowa; University... and other collaboratorsRecruitingPain | Delirium | Critical Illness | Mechanical Ventilation Complication | ICU Acquired Weakness | Implementation ScienceUnited States
-
Johns Hopkins UniversityGilead SciencesCompletedPre-Exposure Prophylaxis (PrEP)United States
-
Kyunghee UniversityNational Research Foundation of KoreaCompleted
-
University of California, IrvineUniversity of California, Los Angeles; National Institute on Minority Health...CompletedLatent Tuberculosis InfectionUnited States
-
University of California, IrvineUniversity of California, Los Angeles; National Institute on Minority Health...CompletedHepatitis C Virus (HCV) InfectionUnited States